A detailed history of Metis Global Partners, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Metis Global Partners, LLC holds 3,533 shares of EXAS stock, worth $203,076. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,533
Holding current value
$203,076
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$42.43 - $70.83 $149,905 - $250,242
3,533 New
3,533 $240,000
Q1 2024

May 06, 2024

SELL
$56.27 - $73.77 $2,982 - $3,909
-53 Reduced 1.46%
3,587 $247,000
Q4 2023

Feb 06, 2024

SELL
$59.06 - $75.72 $175,939 - $225,569
-2,979 Reduced 45.01%
3,640 $269,000
Q3 2023

Nov 07, 2023

BUY
$65.94 - $99.04 $193,402 - $290,484
2,933 Added 79.57%
6,619 $451,000
Q2 2023

Aug 07, 2023

BUY
$62.68 - $95.05 $9,966 - $15,112
159 Added 4.51%
3,686 $346,000
Q1 2023

May 08, 2023

BUY
$47.19 - $70.77 $166,439 - $249,605
3,527 New
3,527 $239,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Metis Global Partners, LLC Portfolio

Follow Metis Global Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metis Global Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Metis Global Partners, LLC with notifications on news.